Comparative Pharmacology
Head-to-head clinical analysis: EXTINA versus GRISEOFULVIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTINA versus GRISEOFULVIN.
EXTINA vs GRISEOFULVIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
Binds to microtubular protein tubulin, disrupting mitotic spindle formation and inhibiting fungal cell mitosis. Also interferes with fungal nucleic acid synthesis and cell wall deposition.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
500 mg orally once daily or 250 mg orally twice daily; microsize formulation: 500-1000 mg orally once daily; ultramicrosize formulation: 330-375 mg orally once daily. Administer with fatty meal to enhance absorption.
None Documented
None Documented
Clinical Note
moderateGriseofulvin + Estrone sulfate
"The metabolism of Estrone sulfate can be increased when combined with Griseofulvin."
Clinical Note
moderateGriseofulvin + Tranilast
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tranilast."
Clinical Note
moderateGriseofulvin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tolfenamic acid."
Clinical Note
moderateGriseofulvin + Nimesulide
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Terminal elimination half-life is 9 to 24 hours; clinically, it allows once or twice daily dosing.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; metabolites excreted in urine (approximately 50%) and feces (approximately 36%) within 24 hours.
Category C
Category D/X
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Nimesulide."